Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
GNI Group ( (JP:2160) ) has issued an announcement.
GNI Group Ltd. reported its consolidated financial results for the second quarter of fiscal year 2025, showing a 4.4% increase in revenue compared to the previous year. However, the company experienced a decline in operating income and pre-tax profit, resulting in a net loss for the period. This financial performance may impact the company’s market positioning and stakeholder confidence as it navigates challenges in the pharmaceutical industry.
The most recent analyst rating on (JP:2160) stock is a Buy with a Yen3700.00 price target. To see the full list of analyst forecasts on GNI Group stock, see the JP:2160 Stock Forecast page.
More about GNI Group
GNI Group Ltd. operates in the pharmaceutical industry, focusing on the development and commercialization of innovative drugs. The company is listed on the Tokyo Stock Exchange and is involved in the research and development of pharmaceutical products, with a market focus on addressing unmet medical needs.
Average Trading Volume: 2,216,427
Technical Sentiment Signal: Buy
Current Market Cap: Yen161.1B
Learn more about 2160 stock on TipRanks’ Stock Analysis page.